Trial Profile
A Multi-centre, Open-label, Randomized Clinical Trial Comparing the Efficacy and Safety of the Antibody-drug Conjugate SYD985 to Physician's Choice in Patients With HER2-positive Unresectable Locally Advanced or Metastatic Breast Cancer
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 15 Dec 2023
Price :
$35
*
At a glance
- Drugs Trastuzumab-duocarmazine (Primary) ; Capecitabine; Eribulin; Lapatinib; Trastuzumab; Trastuzumab; Vinorelbine
- Indications Advanced breast cancer; HER2 positive breast cancer
- Focus Registrational; Therapeutic Use
- Acronyms TULIP
- Sponsors Byondis; Synthon Pharmaceuticals
- 24 Oct 2023 Final Results presented at the 48th European Society for Medical Oncology Congress.
- 22 May 2023 Status changed from active, no longer recruiting to completed.
- 15 May 2023 According to a Byondis media release, the FDA suspends the decision on the product's approvability. The agency requested additional information that requires time and resources that extend beyond the current evaluation period.